NCT04264884Approved For Marketing不适用
Daratumumab Subcutaneous Pre-approval Access Study
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerNCT04599712Janssen Research & Development, LLC
Unknown
不适用
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05503550Janssen Research & Development, LLC
进行中（未招募）
3 期
A Study of DaratumumabMultiple MyelomaMultiple MyelomaMultiple MyelomaNCT05438043Janssen Research & Development, LLC213
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC
Unknown
不适用
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple MyelomaNCT05757973Janssen Research & Development, LLC